Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:TSRX
- CUSIP: 89685K10
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.47
- P/E Growth: N/A
Frequently Asked Questions for Trius Therapeutics (NASDAQ:TSRX)
What is Trius Therapeutics' stock symbol?
Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."
Who are some of Trius Therapeutics' key competitors?
Some companies that are related to Trius Therapeutics include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), Mirati Therapeutics (MRTX), ContraFect Corporation (CFRX), XOMA Corporation (XOMA), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
How do I buy Trius Therapeutics stock?
Shares of Trius Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trius Therapeutics' stock price today?
MarketBeat Community Rating for Trius Therapeutics (NASDAQ TSRX)MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Trius Therapeutics stock can currently be purchased for approximately $13.63.
Consensus Ratings for Trius Therapeutics (NASDAQ:TSRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Trius Therapeutics (NASDAQ:TSRX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Trius Therapeutics (NASDAQ:TSRX)Earnings History by Quarter for Trius Therapeutics (NASDAQ TSRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/6/2013||Q212||($0.33)||($0.41)||$3.71 million||$1.30 million||View||N/A|
Earnings Estimates for Trius Therapeutics (NASDAQ:TSRX)
Current Year EPS Consensus Estimate: $-1.44 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS
Dividend History for Trius Therapeutics (NASDAQ:TSRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Trius Therapeutics (NASDAQ:TSRX)Insider Trades by Quarter for Trius Therapeutics (NASDAQ:TSRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/22/2013||John Finn||Insider||Sell||1,000||$12.10||$12,100.00|| |
|7/15/2013||John Finn||Insider||Sell||3,500||$10.55||$36,925.00|| |
|7/12/2013||John Finn||Insider||Sell||6,500||$9.81||$63,765.00|| |
|7/11/2013||Michael Morneau||CAO||Sell||20,000||$9.75||$195,000.00|| |
|7/1/2013||Philippe Prokocimer||Insider||Sell||2,000||$8.14||$16,280.00|| |
|6/12/2013||John Finn||Insider||Sell||3,000||$9.08||$27,240.00|| |
|6/11/2013||John Finn||Insider||Sell||1,000||$8.94||$8,940.00|| |
|6/4/2013||Ken Bartizal||Insider||Sell||2,000||$7.90||$15,800.00|| |
|6/3/2013||Philippe Prokocimer||Insider||Sell||2,000||$7.75||$15,500.00|| |
|5/24/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.93||$95,160.00|| |
|5/14/2013||Ken Bartizal||Insider||Sell||12,000||$7.85||$94,200.00|| |
|5/14/2013||Michael Morneau||CAO||Sell||20,000||$7.75||$155,000.00|| |
|5/13/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.65||$91,800.00|| |
|5/10/2013||John Finn||Insider||Sell||3,000||$7.48||$22,440.00|| |
Headline Trends for Trius Therapeutics (NASDAQ:TSRX)
Latest Headlines for Trius Therapeutics (NASDAQ:TSRX)
Trius Therapeutics (TSRX) Chart for Friday, July, 21, 2017